Endocrine Research最新文献

{"title":"Study of the rapid vasodilating effect induced by 5β-dihydrotestosterone in the isolated pulmonary arteries of female and male rats.","authors":"Nieves Herrera, Viridiana Miguel, Ángel Cogolludo, Mercedes Perusquía","doi":"10.1080/07435800.2026.2748590","DOIUrl":"https://doi.org/10.1080/07435800.2026.2748590","url":null,"abstract":"<p><strong>Introduction: </strong>The vasoactive androgen 5β-dihydrotestosterone (5β-DHT), which lacks androgenic or estrogenic activity, induces potent vasorelaxation across vascular beds in several mammals, thereby eliciting hypotension. Therefore, a potential vasorelaxation may occur in the pulmonary arteries of rats, which could be relevant to pulmonary arterial hypertension.</p><p><strong>Methodology: </strong>Pulmonary arteries from female and male rats were isometrically recorded and pre-constricted with KCl. 5β-DHT and its precursor, testosterone (T), were tested separately at different concentrations. Cumulative concentration-response curves were obtained, and potency (inhibitory concentration 50) and efficacy were calculated and compared.</p><p><strong>Results: </strong>The potency of T did not differ between females and males. 5β-DHT was 2.2 times more potent than T in females and 6.6 times more potent in males, with greater efficacy than T in males. The rank order of vasodilating potency was: 5β-DHT>>T in females and 5β-DHT >>>>>>>T in males. The acute vasorelaxation of 5β-DHT was operative in the pulmonary arteries of females and males; the effect had a very rapid time course and was reversible after washout. Protein synthesis or transcription inhibitors did not affect its vasodilating effect, indicating that it acts through a nongenomic mechanism in pulmonary arteries.</p><p><strong>Conclusion: </strong>The data showed that 5β-DHT induced stronger nongenomic vasorelaxation than its precursor in females and males, which may be due to their different structural conformations. Pulmonary arteries are a target for this 5β-reduced androgen to induce relaxation.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149180049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sortilin Immunoreactivity Is Associated with Lymphatic and Extrathyroidal Invasion in Medullary Thyroid Carcinoma: A Preliminary Single-Center Study.","authors":"Emre Gezer, Seda Duman Öztürk, Aslı Bala Öcal, Alev Selek, Zeynep Cantürk, Berrin Çetinarslan, Mehmet Sözen","doi":"10.1080/07435800.2026.2733198","DOIUrl":"https://doi.org/10.1080/07435800.2026.2733198","url":null,"abstract":"<p><strong>Introduction: </strong>Medullary thyroid carcinoma (MTC) is a rare aggressive thyroid malignancy lacking reliable molecular markers. Sortilin is associated with tumor invasiveness in several cancers, but its role in MTC remains unclear.</p><p><strong>Methods: </strong>Sortilin immunoreactivity was retrospectively evaluated by immunohistochemistry using both staining percentage and H-score in tumor samples from 24 patients who underwent total thyroidectomy for MTC.</p><p><strong>Results: </strong>All tumors showed sortilin positivity. Higher staining percentage was significantly associated with lymphatic invasion (<i>p</i> = 0.002) and extrathyroidal extension (<i>p</i> = 0.024), whereas the corresponding H-score comparisons did not reach statistical significance (<i>p</i> = 0.106 and <i>p</i> = 0.160, respectively).</p><p><strong>Discussion: </strong>In this preliminary single-center cohort, sortilin staining percentage, but not H-score, was associated with locally invasive histological features. These findings are hypothesis-generating and do not establish sortilin as an independent prognostic biomarker.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the SPARAGMOS Study Protocol: review of a high-dose cabergoline interventional trial in microprolactinomas.","authors":"Matheo A M Stumpf, Andrea Glezer","doi":"10.1080/07435800.2026.2724843","DOIUrl":"10.1080/07435800.2026.2724843","url":null,"abstract":"<p><p>Prolactinoma is the most common subtype of pituitary adenoma, and dopamine agonists are the gold standard for treatment, primarily cabergoline. Current guidelines suggest that transsphenoidal surgery could be offered, especially to young women with noninvasive microprolactinomas, due to its cost-effectiveness. Additionally, concerns regarding the long-term use of dopamine agonists and their lower remission rates have been raised. The SPARAGMOS trial (NCT07463235) will be an interventional, randomized, open-label, multicenter study utilizing a high dose of cabergoline for approximately 6 months to suppress prolactin levels, with the hypothetical goal of achieving greater tumor apoptosis and remission rates. Under this protocol, a remission rate of approximately 70% is hypothesized, similar to that achieved through neurosurgery in specialized pituitary centers or when cabergoline is carefully considered for withdrawal (i.e. treatment duration exceeding 2 years, low dosing, tumor shrinkage, and normoprolactinemia). The control group will receive cabergoline for 2 years at the lowest dose necessary to achieve normoprolactinemia, as per current guidelines. Under these conditions, the remission rate is expected to be low, around 30%. The findings from this trial have the potential to influence and redefine future therapeutic strategies for microprolactinoma.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of serum fibroblast growth factor 19 with DKD as assessed by the UACR and eGFR in patients with type 2 diabetes.","authors":"Yinan Jia, Siyu Liu, Tianli Xu, Xiaojun Cao, Limin Shen, Mengjie Tang","doi":"10.1080/07435800.2026.2727501","DOIUrl":"https://doi.org/10.1080/07435800.2026.2727501","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) is a major complication of type 2 diabetes (T2D). Fibroblast growth factor 19 (FGF19) is a key metabolic regulator, but its relationship with DKD, as defined by estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR), remains unclear.</p><p><strong>Methods: </strong>This cross-sectional study included 330 T2D inpatients and 60 normal controls (NC group). Serum FGF19 levels were measured by ELISA. Renal function was evaluated according to eGFR (CKD-EPI equation) and UACR. Associations between FGF19 levels and renal parameters were analyzed according to Spearman's correlation, partial correlation, and multiple linear regression analyses adjusted for confounders.</p><p><strong>Results: </strong>Serum FGF19 levels were lower in the T2D group than in the NC group (110.25 [68.40-169.32] <i>vs</i>. 242.06 [143.74-319.51] pg/mL, <i>p</i> < 0.001). Among those with T2D, patients with DKD had higher FGF19 levels than those without DKD (122.61 [83.38-189.02] <i>vs</i>. 106.97 [66.54-164.22] pg/mL, <i>p</i> = 0.023). In T2D patients, FGF19 was positively correlated with UACR (<i>r</i> = 0.185; <i>p</i> = 0.005) and inversely correlated with eGFR (<i>r</i> = -0.210; <i>p</i> = 0.001), and these correlations persisted after adjustment for confounders. In fully adjusted linear regression models, FGF19 remained independently associated with a higher UACR (<i>β</i> = 0.203, <i>t</i> = 2.286, <i>p</i> = 0.024) and a lower eGFR (<i>β</i> = -0.170, <i>t</i> = -2.542, <i>p</i> = 0.012). Restricted cubic spline analyses confirmed linear relationships between lnFGF19 and both lnUACR (<i>p</i> = 0.480) and eGFR (<i>p</i> = 0.162).</p><p><strong>Conclusion: </strong>Serum FGF19 levels are independently associated with DKD status in T2D patients; the serum FGF19 level is decreased in T2D patients but relatively elevated in those with DKD. FGF19 levels are independently associated with a higher UACR and a lower eGFR. Restricted cubic spline analyses confirmed linear, rather than nonlinear, associations. These cross-sectional findings suggest an association between FGF19 and diabetic kidney pathology, though the modest effect sizes and study design limit causal interpretation.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of L-Arginine, Myoinositol, and Chromium with Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome: A Randomized Comparative Study.","authors":"Nehal G Abd El-Aziz, Hasnaa Osama, Sara Abdallah Mohamed Salem, Hoda M Rabea","doi":"10.1080/07435800.2026.2713536","DOIUrl":"https://doi.org/10.1080/07435800.2026.2713536","url":null,"abstract":"<p><strong>Background: </strong>PCOS is a hormonal disorder with no medication, hence treatment is symptomatic. Letrozole plus chromium, L-arginine, or myoinositol was tested in PCOS-infertile women.</p><p><strong>Methods: </strong>This prospective trial randomly assigned 240 PCOS patients (<i>n</i> = 60) to one of four groups: letrozole + chromium, L-arginine, myoinositol, or the control. Insulin resistance, testosterone, HOMA-IR, hirsutism, DHEA, and ovulatory function were examined before and after treatment.</p><p><strong>Results: </strong>At each follow-up, all groups showed substantially different ovulation rates (<i>p</i> = 0.026, 0.039, and 0.008 at 1, 2, and 3 months, respectively). Weight, HOMA-IR, and hirsutism were decreased with chromium and myoinositol (<i>p</i> = 0.001). Chromium, myoinositol, and L-arginine significantly reduced testosterone. Myoinositol had the highest pregnancy rates at one and two months (36.7% and 41.9%, respectively). Conclusion: letrozole combined with chromium or myoinositol improves PCOS ovulation, HOMA-IR, and hirsutism.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.9,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemical chaperone TUDCA rescues Insulin-mediated vascular relaxation via ER stress inhibition in diabetic rat model.","authors":"Sagir Mustapha, Ahmad Khusairi Azemi, Aida Hanum Ghulam Rasool, Siti Safiah Mokhtar","doi":"10.1080/07435800.2026.2659582","DOIUrl":"10.1080/07435800.2026.2659582","url":null,"abstract":"<p><strong>Background: </strong>Tauroursodeoxycholic acid (TUDCA) has been shown to improve endothelial dysfunction in type 2 diabetes mellitus (T2DM). However, its role in attenuating endothelial insulin resistance in diabetes is not well understood.</p><p><strong>Objectives: </strong>This study aimed to investigate TUDCA's potential therapeutic effect on endothelial insulin resistance and its underlying mechanisms.</p><p><strong>Methods: </strong>Twenty-seven male Sprague Dawley rats were categorized into control (CON, <i>n</i> = 9), diabetes (DM, <i>n</i> = 9), and diabetes treated with TUDCA (DMT, <i>n</i> = 9). Diabetes was induced using a high-fat diet and low-dose streptozotocin. TUDCA (150 mg/kg) was administered to the DMT group during the last two weeks of a 15-week study. Aortic tissues were analyzed for insulin-mediated relaxation, endoplasmic reticulum (ER) stress markers [inositol-requiring kinase 1 (IRE-1), protein kinase-like ER kinase (PERK), and binding immunoglobulin protein (BIP)], end othelial function markers [endothelial nitric oxide synthase (eNOS), protein kinase B (Akt), and insulinreceptor substrate-1 (IRS-1)], oxidative stress [superoxide dismutase activity (SOD) and malondialdehyde level (MDA)] and inflammation [tumor necrosis factor-alpha (TNF-a)] markers.</p><p><strong>Results: </strong>Insulin-mediated relaxation was impaired in diabetic rats (-56.7%) compared to controls (0%), accompanied by elevated ER stress markers and reduced eNOS, Akt, and IRS-1 expression. TUDCA treatment improved relaxation responses (-6.2%) significantly reduced ER stress markers and restored the expression of endothelial markers.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"119-132"},"PeriodicalIF":1.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nocturnal tissue glycemia is associated with cortisol rise in the morning in young but not in older healthy adults.","authors":"Anika Köhlmoos, Manuela Dittmar","doi":"10.1080/07435800.2026.2664447","DOIUrl":"10.1080/07435800.2026.2664447","url":null,"abstract":"<p><p>Cortisol and vitamin D are known to influence plasma glucose, but their relationship with glycemia, assessed by continuous glucose monitoring, remains unclear for healthy adults. This study compared these relationships between 32 young (26.0 ± 4.8 years) and 25 older (67.3 ± 4.8 years) healthy volunteers. Cortisol was determined at bedtime, awakening, and 30 min (T30) and 60 min (T60) post-awakening. Older adults had higher fasting glucose but lower cortisol concentration at T30 than young adults. In young adults, night- and daytime mean glucose and fasting glucose correlated negatively with cortisol at T30, while glycemic variability correlated positively with cortisol at T60. Vitamin D correlated negatively with nighttime mean glucose in the young group. In conclusion, glucose concentration and glycemic variability are associated with the cortisol response the following morning. The lack of these associations in older adults could be explained by their higher fasting glucose concentrations resulting in a lower morning cortisol response.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"133-141"},"PeriodicalIF":1.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interaction between eGDR and visceral adiposity in renal function decline among middle-aged and elderly diabetes patients: findings from a nationwide Chinese cohort.","authors":"Yan Chen, Zhihai Feng","doi":"10.1080/07435800.2026.2671747","DOIUrl":"10.1080/07435800.2026.2671747","url":null,"abstract":"<p><strong>Background: </strong>Both insulin resistance and visceral adiposity, which can be measured by the estimated Glucose Disposal Rate (eGDR) and Chinese Visceral Adiposity Index (CVAI), are related to the decline of renal function in diabetes patients, but the relationship between them and renal function decline in diabetes patients remains unclear.</p><p><strong>Aim: </strong>To explore the independent and interaction effect of eGDR and CVAI on the renal function of diabetes patients.</p><p><strong>Method: </strong>Data were obtained from the China Health and Retirement Longitudinal Study (CHARLS) 2011 and 2015. In this study, eGDR and CVAI were firstly treated as numeric variables, and then wereclassified into \"low\" and \"high\" groups, respectively, based on their median values. Logistic and linear regression models were applied to explore the relationship between eGDR, CVAI and rapid renal function decline and  ΔeGFR. Multiplicative and additive interaction analyses were conducted to evaluate interaction between the two indexes. Subgroup analysis was then conducted to explore the independent and interaction effect of them across different population.</p><p><strong>Results: </strong>A total of 1133 participants were selected to participate in the study. Multivariate logistic regression results revealed significant independent positive association of high CVAI with rapid decline of renal function, but no significant relationship between low eGDR, interaction and rapid decline of renal function were observed. Linear regression results indicated that both low eGDR and high CVAI had a negative relationship with ΔeGFR, and the interaction was significant. The results of subgroup analyses were consistent with the main analyses.</p><p><strong>Conclusion: </strong>High CVAI was observed to be related with rapid decline of renal function, while no significant relationship of eGDR, interaction, and rapid decline of renal function was observed. Low eGDR and high CVAI are negative associated with ΔeGFR, respectively. Notably, there exists multiplicative interaction betweenthem on ΔeGFR.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"142-153"},"PeriodicalIF":1.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body composition and cardiometabolic changes during gender-affirming hormone therapy: 12-month longitudinal study.","authors":"Elif Seray Korkmaz, Ahmet Toygar Kalkan, Aysen Akalın, Medine Nur Kebapçı, Ertuğrul Çolak, Göknur Yorulmaz","doi":"10.1080/07435800.2026.2692682","DOIUrl":"10.1080/07435800.2026.2692682","url":null,"abstract":"<p><strong>Background: </strong>Testosterone therapy induces well-known changes in body composition in transgender men; however, its short-term cardiometabolic effects remain incompletely characterized. This study aimed to evaluate body composition and cardiometabolic changes during testosterone therapy over a 12-month period.</p><p><strong>Methods: </strong>This retrospective observational study included 15 transgender men initiating intramuscular testosterone therapy who were followed for 12 months. Anthropometric measurements, body composition, blood pressure, and laboratory parameters including lipid profile, fasting glucose, HbA1c, plasma atherogenic index (PAI), and triglyceride-glucose (TyG) index were assessed at baseline and at 12 months. All participants initiated intramuscular depot testosterone therapy administered every 28 days. None of the participants underwent oophorectomy during the study period.</p><p><strong>Results: </strong>Total testosterone levels increased significantly from 40.82 ± 19.46 ng/dL to 338.06 ± 205.02 ng/dL (<i>p</i> < 0.001), while estradiol levels remained stable. Systolic blood pressure and mean arterial pressure showed mild but non-significant increases during follow-up. Body weight, body mass index, and fat-free mass increased significantly, while body fat percentage decreased. HDL cholesterol levels decreased (59.7 ± 11.2 to 52.3 ± 13.2 mg/dL, <i>p</i> = 0.019), and triglyceride levels showed a non-significant upward trend. The PAI increased from 0.08 ± 0.24 to 0.23 ± 0.25 (<i>p</i> = 0.017), and the TyG index rose from 8.02 ± 0.43 to 8.21 ± 0.39 (<i>p</i> = 0.016). Blood pressure parameters did not change significantly.</p><p><strong>Conclusions: </strong>In transgender men without oophorectomy, testosterone therapy was associated with favorable changes in body composition alongside modest shifts in cardiometabolic indices over a 12-month period. These findings suggest that simple indices such as PAI and TyG may be useful for monitoring early cardiometabolic changes attributable to exogenous testosterone therapy. Larger prospective studies are warranted to confirm these observations.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"154-162"},"PeriodicalIF":1.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148327563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MMRN1 suppresses thyroid cancer progression via activation of the Hippo signaling pathway.","authors":"Meihua Zhang, Junjun Guo, Jun Sun, Xiaoling Gao, Yan Lv","doi":"10.1080/07435800.2026.2694492","DOIUrl":"10.1080/07435800.2026.2694492","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid cancer (TC) represents the most frequently diagnosed malignancy of the endocrine system, with its incidence continuing to increase worldwide. Multimerin 1 (MMRN1), a glycoprotein implicated in various cancers, exhibits context-dependent roles, but its function in TC remains unexplored. The Hippo pathway, a key regulator of cell proliferation and apoptosis, is frequently dysregulated in TC. We hypothesized that MMRN1 inhibits TC progression by activating the Hippo signaling pathway.</p><p><strong>Methods: </strong>Bioinformatics analysis of GSE33630 identified differentially expressed genes (DEGs) in TC. MMRN1 expression was validated in TC cell lines (BCPAP, TPC-1, IHH-4, HTH83) and normal thyroid cells (NTHY-ORI3.1) via RT-qPCR and Western blot. Functional assays assessed proliferation, migration, and invasion. Hippo pathway activity was evaluated after MMRN1 modulation. Oxidative stress and ferroptosis markers (ROS, SOD, CAT, GSH, MDA, GPX4, TF, TFR1) were analyzed.</p><p><strong>Results: </strong>MMRN1 was downregulated in TC tissues and cell lines. Overexpression of MMRN1 suppressed TC cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, MMRN1 activated Hippo signaling, increasing p-MST1/2, p-LATS1/2, and p-YAP levels. Verteporfin reversed these effects. Additionally, MMRN1 modulated oxidative stress markers (including ROS and the indirect lipid peroxidation marker MDA) and altered GPX4 activity and iron metabolism, suggesting enhanced ferroptosis sensitivity.</p><p><strong>Conclusion: </strong>MMRN1 acts as a tumor suppressor in TC by activating the Hippo pathway and modulating oxidative stress and ferroptosis. These findings highlight MMRN1 as a potential therapeutic target for TC treatment.</p>","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":" ","pages":"178-192"},"PeriodicalIF":1.9,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}